271 related articles for article (PubMed ID: 29991347)
1. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial.
Kato T; Furukawa TA; Mantani A; Kurata K; Kubouchi H; Hirota S; Sato H; Sugishita K; Chino B; Itoh K; Ikeda Y; Shinagawa Y; Kondo M; Okamoto Y; Fujita H; Suga M; Yasumoto S; Tsujino N; Inoue T; Fujise N; Akechi T; Yamada M; Shimodera S; Watanabe N; Inagaki M; Miki K; Ogawa Y; Takeshima N; Hayasaka Y; Tajika A; Shinohara K; Yonemoto N; Tanaka S; Zhou Q; Guyatt GH;
BMC Med; 2018 Jul; 16(1):103. PubMed ID: 29991347
[TBL] [Abstract][Full Text] [Related]
2. Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol.
Furukawa TA; Akechi T; Shimodera S; Yamada M; Miki K; Watanabe N; Inagaki M; Yonemoto N
Trials; 2011 May; 12():116. PubMed ID: 21569309
[TBL] [Abstract][Full Text] [Related]
3. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
Banerjee S; Hellier J; Romeo R; Dewey M; Knapp M; Ballard C; Baldwin R; Bentham P; Fox C; Holmes C; Katona C; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; Orrell M; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Burns A
Health Technol Assess; 2013 Feb; 17(7):1-166. PubMed ID: 23438937
[TBL] [Abstract][Full Text] [Related]
4. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
5. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
[TBL] [Abstract][Full Text] [Related]
6. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Banerjee S; Hellier J; Dewey M; Romeo R; Ballard C; Baldwin R; Bentham P; Fox C; Holmes C; Katona C; Knapp M; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; Orrell M; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Burns A
Lancet; 2011 Jul; 378(9789):403-11. PubMed ID: 21764118
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
[TBL] [Abstract][Full Text] [Related]
9. The first 100 patients in the SUN(^_^)D trial (strategic use of new generation antidepressants for depression): examination of feasibility and adherence during the pilot phase.
Shimodera S; Kato T; Sato H; Miki K; Shinagawa Y; Kondo M; Fujita H; Morokuma I; Ikeda Y; Akechi T; Watanabe N; Yamada M; Inagaki M; Yonemoto N; Furukawa TA;
Trials; 2012 Jun; 13():80. PubMed ID: 22682213
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of mirtazapine as add-on to paroxetine
Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
[TBL] [Abstract][Full Text] [Related]
11. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological interventions for treatment-resistant depression in adults.
Davies P; Ijaz S; Williams CJ; Kessler D; Lewis G; Wiles N
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD010557. PubMed ID: 31846068
[TBL] [Abstract][Full Text] [Related]
13. Can personalized treatment prediction improve the outcomes, compared with the group average approach, in a randomized trial? Developing and validating a multivariable prediction model in a pragmatic megatrial of acute treatment for major depression.
Furukawa TA; Debray TPA; Akechi T; Yamada M; Kato T; Seo M; Efthimiou O
J Affect Disord; 2020 Sep; 274():690-697. PubMed ID: 32664003
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.
Lewis G; Duffy L; Ades A; Amos R; Araya R; Brabyn S; Button KS; Churchill R; Derrick C; Dowrick C; Gilbody S; Fawsitt C; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Khan N; Lanham P; Pervin J; Peters TJ; Riozzie D; Salaminios G; Thomas L; Welton NJ; Wiles N; Woodhouse R; Lewis G
Lancet Psychiatry; 2019 Nov; 6(11):903-914. PubMed ID: 31543474
[TBL] [Abstract][Full Text] [Related]
15. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.
Hedayati SS; Gregg LP; Carmody T; Jain N; Toups M; Rush AJ; Toto RD; Trivedi MH
JAMA; 2017 Nov; 318(19):1876-1890. PubMed ID: 29101402
[TBL] [Abstract][Full Text] [Related]
16. A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
Banerjee S; Farina N; Henderson C; High J; Stirling S; Shepstone L; Fountain J; Ballard C; Bentham P; Burns A; Fox C; Francis P; Howard R; Knapp M; Leroi I; Livingston G; Nilforooshan R; Nurock S; O'Brien J; Price A; Thomas AJ; Swart AM; Telling T; Tabet N
Health Technol Assess; 2023 Oct; 27(23):1-108. PubMed ID: 37929672
[TBL] [Abstract][Full Text] [Related]
17. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
18. Sertraline with desvenlafaxine and sertraline with mirtazapine as treatment initiation in MDD patients with moderate to severe depression and effect on inflammatory markers.
Arockiaraj N; Gupta R; Ahmad R; Halder S; Bhatia MS
Int J Psychiatry Clin Pract; 2024 Mar; 28(1):9-16. PubMed ID: 38019131
[TBL] [Abstract][Full Text] [Related]
19. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
